Zanolimumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) Added mab_type, updated source |
m Stub sorting and placement of stub template(s) |
||
Line 37: | Line 37: | ||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
{{antineoplastic-drug-stub}} |
Revision as of 12:56, 29 July 2010
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
Chemical and physical data | |
Molar mass | 147 kDa |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, cutaneous and peripheral T-cell lymphoma.[2][3]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov